Great article pumper, did you read the whole thing??
"Despite these recent financing activities, FOXO has stated that, based on its current operations, it does not have sufficient capital to fund its operations for at least 12 months from the date of its latest financial statements. The company expects to continue to incur operating losses until it is able to finalize the acquisition of RCHI and generate positive cash flows from the combined operations.
Risks and Challenges
FOXO faces several risks and challenges that could impact its future performance. The company has a history of losses and may not achieve or maintain profitability in the future. It also faces the potential inability to establish or maintain the relationships required to advance its goals or achieve its commercialization and development plans.
Additionally, FOXO’s business is subject to the highly regulated nature of the biotechnology and insurance industries, which could lead to changes in laws and regulations that adversely affect the company’s operations. The enforceability of FOXO’s intellectual property, including its patents, and the potential infringement on the intellectual property rights of others also pose risks.
The company’s continued listing on the NYSE American exchange is also a concern, as FOXO has received notices of noncompliance with certain continued listing standards. While the company is working to regain compliance, there is no assurance that it will ultimately be successful in doing so."
News 
Market Data 
Discover 
AI
